NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Sample GSM1660550 Query DataSets for GSM1660550
Status Public on Oct 01, 2015
Title UPN727 cells, AIDA PL22 at 9 month
Sample type RNA
 
Source name UPN727 cells stimulated with AIDA_PL22_M9 serum
Organism Homo sapiens
Characteristics responder cells: UPN727 cells
patient: PL22
timepoint: 9 month into treatment
Treatment protocol Gene expression was accomplished by culturing PBMCs at 37°C in 5% CO2 with 40% serum from recent-onset (RO) T1D patients that were given Placebo or Anakinra at their respective time points. Cultures were prepared in a Costar 24-well plate (Corning) using 500,000 cells/well and in RPMI 1640 medium supplemented with 100U/ml penicillin and 100ug/ml streptomycin in a total of 500 µl. After culture (9 hours optimal for cryopreserved PBMCs) total RNA was extracted using TRIzol reagent (Invitrogen Life Technologies).
Growth protocol Commercial cryopreserved PBMCs of healthy Caucasian male donor UPN727 were thawed and washed per the manufacturer’s protocol (Cellular Technology Ltd., Shaker Heights, OH).
Extracted molecule total RNA
Extraction protocol Trizol extraction of total RNA was performed according to the manufacturer's instructions.
Label biotin
Label protocol Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).
 
Hybridization protocol Purified total RNA (~50ng) was amplified using the two-cycle cDNA synthesis kit (Affymetrix 900432) and cRNA was synthesized, labeled, fragmented and hybridized to the arrays in accordance to standard Affymetrix protocols (Affymetrix, Santa Clara, CA)
Scan protocol GeneChips were scanned using the GeneChip Scanner 3000.
Description Gene expression data from UPN727 cells stimulated with serum collected from patient PL22 9 month into treatment
Data processing Image data were normalized and analyzed Partek Genomic Suite (Partek GS) to determine signal log intensities. Each sample was independently analyzed (5 arrays per patient, at baseline, 1, 3, 6, and 9 months into treatment, 235 arrays in total). The statistical significance of differential gene expression and false discovery rates (FDR) were derived through ANOVA as a statistic analysis method in Partek GS.
 
Submission date Apr 16, 2015
Last update date Oct 01, 2015
Contact name Martin Hessner
E-mail(s) mhessner@mcw.edu
Organization name Medical College of Wisconsin
Department Pediatrics
Lab Max McGee National Research Center for Juvenile Diabetes
Street address 8701 Watertown Plank Road
City Milwaukee
State/province WI
ZIP/Postal code 53226
Country USA
 
Platform ID GPL570
Series (1)
GSE37025 Interleukin-1 receptor antagonist for recent-onset type 1 diabeties mellitus: a multicenter randomized, placebo-controlled trial

Data table header descriptions
ID_REF
VALUE RMA normalized log2 Intensity.

Data table
ID_REF VALUE
1007_s_at 6.52827
1053_at 6.46933
117_at 4.46431
121_at 6.44227
1255_g_at 2.13297
1294_at 7.09153
1316_at 5.65235
1320_at 2.60897
1405_i_at 10.6972
1431_at 2.47179
1438_at 3.79046
1487_at 6.22105
1494_f_at 4.94731
1552256_a_at 4.60333
1552257_a_at 6.05886
1552258_at 4.61207
1552261_at 2.84928
1552263_at 6.3512
1552264_a_at 6.61521
1552266_at 1.80098

Total number of rows: 54675

Table truncated, full table size 998 Kbytes.




Supplementary file Size Download File type/resource
GSM1660550_100_s209_AIDA_PL22_M9_7-20-12_HG-U133_Plus_2_.CEL.gz 4.0 Mb (ftp)(http) CEL
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap